Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Recombinant Factor IX (BAX 326): A Phase 1/3, Prospective, Controlled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety and Immunogenicity in Previously Treated Patients With Severe or Moderately Severe Hemophilia B

NCT01174446 is registered in ClinicalTrials.gov with Baxalta now part of Shire as lead sponsor.

NCT NCT01174446
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01174446 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Recombinant Factor IX (BAX 326): A Phase 1/3, Prospective, Controlled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety and Immunogenicity in Previously Treated Patients With Severe or Moderately Severe Hemophilia B
Lead sponsor
Baxalta now part of Shire
Phase
Phase 3
Overall status
Completed
Start date
July 29, 2010
Completion date
May 3, 2012
Enrollment
86 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia b